Because existing noninvasive NASH evaluation strategies using the AST/ALT ratio are derived mainly from patients with chronic hepatitis and have not been validated in different ethnicities or at multiple centres [23], we then had given up the analysis of the risk factors for AST/ALT ≥ 1.0 or 0.8. The gene discussed is GPT; the disease is chronic hepatitis.